Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use

References to Primarv Literature

• PERELSON AS, NEUMANN AU, MARKOWITZ M, LEONARDJM, HO DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 271:1582–1586,
   PubMed Web of Science ®Google Scholar
• HO DD, NEUMANN AU, PERELSON AS et al.: Rapid turn-over of plasma virions and CD4 lymphocytes in HIV-1 Infection. Nature (1995) 373:123–126.
   PubMed Web of Science ®Google Scholar
• WEI X, GHOSH SK, TAYLOR ME et al.: Viral dynamics inhuman immunodeficiencyvirus type 1 infection. Nature (1995) 373:117–122.
   PubMed Web of Science ®Google Scholar
• COFFIN JM: HIV population dynamics in vivo: implica-tions for genetic variation, pathogenesis and therapy. Science (1995) 267:483–489.
   PubMed Web of Science ®Google Scholar
• MELLORS JW, KINGSLEY LA, RINALDO CR et al.: Quantita-tion of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. (1995) 122:573–579.
   Google Scholar
• MELLORS JW, RINALDO CR, GUPTA P et al.: Prognosis inHP/-1 infection predicted by the quantity of virus in plasma Science (1996) 272:1167–1170.
   Google Scholar
• RICHMAN DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. An-timicrob. Agents Chemother. (1993) 37:1207–1213.
   PubMed Web of Science ®Google Scholar
• LARDER BA, KEMP SD, HARRIGAN PR: Potential mecha-nism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 269:696–699.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, HAVLIR D, CORBEIL J et al.: Nevirapine resistance mutations of human immunodeficiency vi-rus type 1 selected during therapy. J. Virol. (1994) 68:1660–1666.
   PubMed Web of Science ®Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ MI et al.: Treat-ment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of 111V-1-specific Inhibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. (1993) 67:5353–5359.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, RAMIREZ-RONDA C, LANGE JMA et al.: Virologic and immunologic benefits of initial combina-tion therapy with zidovudine and zalcitabine or di-danosine compared with zidovudine monotherapy. J. Infect. Dis. (1996) 173:1354–1366.
   PubMed Web of Science ®Google Scholar
• CAMERON B, HEATH-CHIOZZI M, DRAVCIK S et al.: Pro-longation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. In: Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections Washington, DC (1996). Abstract # LB6a.
   Google Scholar
• GULICK R, MELLORS J, HAVLIR D et al.: Potent and sustained antiretroviral activity of indinavir (IDV), zi-dovudine (ZDV) and lanaivudine (3TC). In: Abstracts of the XIth International Conference on AIDS. Vancouver (1996). Abstract # Th.B.931.
   Google Scholar
• COLLIER AC, COOMBS RW, SCHOENFELD DA et al.: Treat-ment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalchabine. NetvEngl.J. Med. (1990 334:1011–1017.
   Google Scholar
• D'AQUILA RT, HUGHES MD, JOHNSON VA et al.: Nevirap-ine, zidovudine, and didanosine compared with zi-dovudine and didanosine in patients with HIV-1 Infection, a randomized, double-blind, placebo-con-trolled trial. Ann. Intern Med. (1996) 124:1019–1030.
   Google Scholar
• STASZEWSKI S, MHI.FR V, REHMET S et al.: Virologic and Immunologic analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS (1996) 10:F1–F7.
   Google Scholar
• MYERS MW, MONTANER JG, THE INCAS STUDY GROUP: A randomized, double-blind comparative trial of the effects of zidovudine, didanosine and nevirapine com-binations in antiviral naive, AIDS-free, H1V-infected patients with CD4 counts 200-600/mm3. In: Abstracts of the XIth International Conference on AIDS. Vancouver (1996). Abstract #Mo.B.294.
   Google Scholar
• CAMERON W, SUN E, MARKOWITZ M et al.: Combinationuse of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data. In: Abstracts of the XIth International Conference on AIDS. Vancouver (1996) Abstract #Th.B.934.
   Google Scholar
• BACOLLA A, SHIII CK, ROSE JM et al.: Amino acid substi-tutions in H1V-1 reverse transcriptase with correspond-ing residues from HIV-2: effect on kinetic constants and inhibition by non-nucleoside analogs. J. Biol. Chem. (1993) 268:1657–1677.
   Google Scholar
• SMERDON SJ, JAGER J, WANG J et al.: Structure of thebinding site for notmucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1994) 26:3911–3915.
   Web of Science ®Google Scholar
• DING J, DAS K, MOEREELS H et al.: Structure of HIV-1RT/TIRO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol (1995) 2:407–415.
   PubMedGoogle Scholar
• MERRILL DP, MOONIS M, CHOU TC, HIRSCH MS: Lami-vudine or stavudine in two- and three-drug combina-tions against human iramunodeficiency virus type 1 replication in vitro. J Infect. Dis. (1996) 173:355–364•
   Google Scholar
• GU Z, QUAN Y, LI Z, ARTS EJ, WAINBERG MA: Effects of non-nucleoside inhibitors of human immunodefi-ciency virus type 1 in cell-free recombinant reverse transcriptase assays. J. Biol. Chem. (1995) 270:31046–31051.
   PubMed Web of Science ®Google Scholar
• ST CLAIR MH, PENNINGTON KN, ROONEY J, BARRY DW: In vitro comparison of selected triple-drug combina-tions for suppression of H1V-1 replication: the Inter-Company Collaboration ProtocoL J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1995) 10\(Suppl. 2):S83–591.
   Google Scholar
• KOUP RA, BREWSTER F, GROB P, SULLIVAN JL: Nevirapine synergistically inhibits HIV-1 replication in combina-tion with zidovudine, interferon or CD4 irrununoadhe-sin. AIDS (1993) 7:1181–1184.
   PubMed Web of Science ®Google Scholar
• LARDER BA: 3'-Aziclo-3'-deoxythyraidine resistance sup-pressed by a mutation conferring human immunodefi-ciency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1992) 36:2664–2669.
   PubMed Web of Science ®Google Scholar
• SPENCE RA, ANDERSON KS, JOHNSON KA: HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry (1996) 35:1054–1063.
   PubMed Web of Science ®Google Scholar
• NAJERA I, RICHMAN DD, OLIVARES 1 et al.: Natural occur-rence of drug resistance mutations in the reverse tran-scriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroviruses (1994) 10:1479–1488.
   Google Scholar
• BALZARINI J, KARLSSON A, DE CLERCQ E: Human immu-nodeficiency virus type 1 drug-resistance patterns with different 1[(2-hydroxyethoxy)methy11-6-(phenylthio) thymine derivatives. Mol. Pbarrnacol. (1993) 44:694–701,
   PubMed Web of Science ®Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ MJ, CAMARASA MJ, DE CLERCQ E: Knocking-out concentrations of HIV-1-specific inhibitors completely suppresses mV-1 infec-tion and prevents the emergence of drug-resistant virus. Virology (1993) 196:576–585.
   PubMed Web of Science ®Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ JM et al.: Treat-ment of human Immunodeficiency virus type 1 (111V-1) Infected cells with combinations of HIV-1-specific in-hibitors results in a different resistance pattern than does treatment with single-drug therapy. J. Virol. (1993) 67:5353–5359.
   PubMed Web of Science ®Google Scholar
• DUEWEKE TJ, PUSHKARSKAYA T, POPPE SM et al.: A mutation in reverse transcriptase of bis(het-eroaryl)piperazine-resistant human immunodefi-ciency virus typel that confers increased sensitivity to other nonnucleoside inhibitors. Proc . Natl. Acad. Sci. USA (1993) 90:4713–4717.
   PubMed Web of Science ®Google Scholar
• MELLORS JW, IM GJ, TRAMONTANO E et al.: A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 con-fers resistance to (+)-(55)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5,1-jk][1,4] benzodiazepin-2(1H)-thione (TIRO R82150). Mol. Phar-macol. (1993) 43:11–16.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD: Resistance, drug failure, and diseaseprogression. AIDS Res. Hum. Retroviruses (1994) 10:901–905.
   PubMed Web of Science ®Google Scholar
• BYRNES VW, SARDANA VV, SCHLEIF WA et al.: Compre-hensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse tran-scriptase resistance to nonnucleoside inhibitors. An-timicrob. Agents Chemother. (1993) 37:1576–1579.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Toward improved anti-HIV chemother-apy: therapeutic strategies for intervention with HIV Infection. J. Med. Chem. (1995) 38:2491–2517.
   PubMed Web of Science ®Google Scholar
• RICIIMAN D, SHIH CK, LOWY I et al.: Human inununode-ficiency virus type 1 mutations resistant to nonnu-cleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA (1991) 88:11241–11245.
   PubMed Web of Science ®Google Scholar
• HAVLIR D, MCLAUGHLIN MM, RICHMAN DD: A pilot studyto evaluate the development of resistance to nevirapine In asymptomatic human immunodeficiency virus-in-fected patients with CD4 cell counts of 500/mm3: AIDS Clinical Trials Group Protocol 208. J. Infect. Dis. (1995) 172:1379–1383.
   PubMed Web of Science ®Google Scholar
• DE JONG MD, LOEWENTHAL M, BOUCHER CA et al.: Alternating nevirapine and zidovudine treatment of human inununodeficiency virus type- 1-infected per-sons does not prolong nevirapine activity. J. Infect. Dis. (1994) 169:1346–1350.
   PubMed Web of Science ®Google Scholar
• CIIEESEMAN SH, HATTOX SE, MCLAUGHLIN MM ci al.: Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob. Agents Cbemother. (1993) 37:178–182.
   PubMed Web of Science ®Google Scholar
• HAVLIR D, CHEESEMAN S11, MCLAUGHLIN M et al.: High-dose nevirapine: safety, pharmacokinetics, and antivi-ral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. (1995) 171:537–545.
   Google Scholar
• CHEESEMAN SI I, HAVLIR D, MCLAUGHLIN MM et al.: Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunode-ficiency virus. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. (1995) 8:141–151.
   PubMedGoogle Scholar
• MURPHY RL, HAVLIR D, SAAG MS, CIIEESEMAN Si l, DRANSFIELD K: Safety, immunologic, and virologic ac-tivity of nevirapine in combination with zidovudine therapy in HIV-infected patients. Program and Abstracts of the 2nd Conference on Human Retroviruses and Related Infections. Washington, DC (1995). Abstract #262.
   Google Scholar
• PAAR D, POLLARD R, HALL D, MYERS M, ROBINSON P: Nevirapine (NVP) in combination with zidovudine (ZDV) vs. ZDV in nucleoside experienced patients. Pro-gram, IDSA Annual Meeting. San Francisco (1995). Abstract #383.
   Google Scholar